SLS BIO Co., Ltd
SLS BIO Co., Ltd develops diagnostic technologies in South Korea. It offers pharmaceuticals quality control testing services, including pharmaceutical equivalence study, raw materials/finished drugs test, and other analysis testing services; and efficacy evaluation services, such as immune function-based efficacy evaluation and pharmacokinetics and toxicokinetics analysis services. In addition, i… Read more
Market Cap & Net Worth: SLS BIO Co., Ltd (246250)
SLS BIO Co., Ltd (KQ:246250) has a market capitalization of $12.28K (₩17.99 Million) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #44497 globally and #2545 in its home market, demonstrating a -4.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SLS BIO Co., Ltd's stock price ₩1969.00 by its total outstanding shares 9135 (9.13K).
SLS BIO Co., Ltd Market Cap History: 2023 to 2025
SLS BIO Co., Ltd's market capitalization history from 2023 to 2025. Data shows change from $15.78K to $12.28K (-23.79% CAGR).
SLS BIO Co., Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SLS BIO Co., Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 246250 by Market Capitalization
Companies near SLS BIO Co., Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to SLS BIO Co., Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
SLS BIO Co., Ltd Historical Marketcap From 2023 to 2025
Between 2023 and today, SLS BIO Co., Ltd's market cap moved from $15.78K to $ 12.28K, with a yearly change of -23.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ₩12.28K | +2.29% |
| 2024 | ₩12.01K | -23.88% |
| 2023 | ₩15.78K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SLS BIO Co., Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.28K USD |
| MoneyControl | $12.28K USD |
| MarketWatch | $12.28K USD |
| marketcap.company | $12.28K USD |
| Reuters | $12.28K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.